File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment
Title | Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Association for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org |
Citation | The Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, MD, 7-11 May 2017. In Investigative Ophthalmology & Visual Science, 2017, v. 58, p. 3205 How to Cite? |
Abstract | Purpose : To evaluate cytokines level in aqueous humor of ranibizumab (RN) non-responders with neovascular AMD (nAMD) who were treated with either combination of ranibizumab (RN), and photodynamic therapy (PDT) or aflibercept (AF) and explore the prediction cytokines for RN non-responders
Methods : This prospective study collected aqueous specimen prospectively from RN non-responder receiving either AF or combination PDT (Study gr.) and RN responders patients (Control gr.) for cytokine analysis at baseline, month 1, 2 and 3 visit of treatment. Cytokines level and changes in 3 treatment groups were compared by using GLMM. Weighted propensity score was used to adjusted for covariate. VEGF, PDGF,PLGF and others angiogenesis/inflammatory cytokines were analyzed by Bio-Plex® Multiplex Immunoassays.
Results : Eleven, 8 and 13 eyes received AF treatment, combined PDT, and control respectively. Mean change of visual acuity from baseline is improved [WC1] in the control gr. (P<0.05) while study gr. didn’t show significant changes. In PDT group, 75% of patients showed stabilization or improvement in AMD clinical activity while PLGF, PDGF and leptin level are significant increase at first month: At 2 months visit, VEGF-A level is increase while Endoglin and HB-EGF decline when compare to baseline. At 3 months visit, VEGF-C and HGF concentration are higher in AF group than control group (p=0.02 and 0.02). There are no different in PLGF,PDGF,VEGF-A levels between each treatment group in all visit. PLGF level was higher in study gr. while IL-7 was lower in study gr. (P=0.02 and 0.04 respectively). The combination level of Angiopoetin 2, IL-6, ICAM, Follistatin and IL-3 can predict the response of RN treatment with 83% sensitivity and 72% specificity.
Conclusions : Switching to AF may not reduce major cytokines level but resulted in improvement of visual acuity. Combination of PDT and RN resulted increase angiogenesis cytokines. The lack of IL-7 was found in non-responder patient. Apart from cytokine levels, other factors such as cytokine receptors and immune system activity may play a role in non-response patient. |
Persistent Identifier | http://hdl.handle.net/10722/248283 |
ISSN | 2023 Impact Factor: 5.0 2023 SCImago Journal Rankings: 1.422 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pongsachareonnont, P | - |
dc.contributor.author | Lam, WC | - |
dc.contributor.author | Mak, MYK | - |
dc.date.accessioned | 2017-10-18T08:40:46Z | - |
dc.date.available | 2017-10-18T08:40:46Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | The Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, MD, 7-11 May 2017. In Investigative Ophthalmology & Visual Science, 2017, v. 58, p. 3205 | - |
dc.identifier.issn | 0146-0404 | - |
dc.identifier.uri | http://hdl.handle.net/10722/248283 | - |
dc.description.abstract | Purpose : To evaluate cytokines level in aqueous humor of ranibizumab (RN) non-responders with neovascular AMD (nAMD) who were treated with either combination of ranibizumab (RN), and photodynamic therapy (PDT) or aflibercept (AF) and explore the prediction cytokines for RN non-responders Methods : This prospective study collected aqueous specimen prospectively from RN non-responder receiving either AF or combination PDT (Study gr.) and RN responders patients (Control gr.) for cytokine analysis at baseline, month 1, 2 and 3 visit of treatment. Cytokines level and changes in 3 treatment groups were compared by using GLMM. Weighted propensity score was used to adjusted for covariate. VEGF, PDGF,PLGF and others angiogenesis/inflammatory cytokines were analyzed by Bio-Plex® Multiplex Immunoassays. Results : Eleven, 8 and 13 eyes received AF treatment, combined PDT, and control respectively. Mean change of visual acuity from baseline is improved [WC1] in the control gr. (P<0.05) while study gr. didn’t show significant changes. In PDT group, 75% of patients showed stabilization or improvement in AMD clinical activity while PLGF, PDGF and leptin level are significant increase at first month: At 2 months visit, VEGF-A level is increase while Endoglin and HB-EGF decline when compare to baseline. At 3 months visit, VEGF-C and HGF concentration are higher in AF group than control group (p=0.02 and 0.02). There are no different in PLGF,PDGF,VEGF-A levels between each treatment group in all visit. PLGF level was higher in study gr. while IL-7 was lower in study gr. (P=0.02 and 0.04 respectively). The combination level of Angiopoetin 2, IL-6, ICAM, Follistatin and IL-3 can predict the response of RN treatment with 83% sensitivity and 72% specificity. Conclusions : Switching to AF may not reduce major cytokines level but resulted in improvement of visual acuity. Combination of PDT and RN resulted increase angiogenesis cytokines. The lack of IL-7 was found in non-responder patient. Apart from cytokine levels, other factors such as cytokine receptors and immune system activity may play a role in non-response patient. | - |
dc.language | eng | - |
dc.publisher | Association for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org | - |
dc.relation.ispartof | Investigative Ophthalmology & Visual Science | - |
dc.title | Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Lam, WC: waichlam@hku.hk | - |
dc.identifier.authority | Lam, WC=rp02162 | - |
dc.identifier.hkuros | 281925 | - |
dc.identifier.volume | 58 | - |
dc.identifier.spage | 3205 | - |
dc.identifier.epage | 3205 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0146-0404 | - |